Doxorubicin and imatinib co-loaded pegylated nanostructured carriers to effectively overcome doxorubicin resistance in metastatic tumors

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-FDP-036
• By: YONG, Chul Soon (Yeungnam University, Gyeongsan-Si, Korea, Republic Of)
• Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Biki Gupta: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Shiva Pathak: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Raj Kumar Thapa: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Jee-Heon Jeong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
  Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
  Chul Soon Yong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  Jong Oh Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  
• Abstract:

  Background

  Resistance to chemotherapeutic agents is viewed as a major impediment to successful treatment of metastatic cancers. Doxorubicin(DOX) is often associated with recurrence or metastasis of cancers, primarily as a result of development of multidrug resistance(MDR).

  Purpose

  The purpose was to prepare PEGylated-nanostructured platforms for..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login